skip to Main Content

PureTech Presents Data About Two Promising Anti-cancer Therapies

Newsfeed image, light gray text on dark gray background

PureTech Health is developing two promising candidate therapies that target key immunosuppressive mechanisms in cancer and may be used against cancers that fail to respond to existing immunotherapy approaches.

The antibodies — LYT-200 and LYT-210 — were developed to inhibit the Galectin-9 protein and gamma delta 1 (γδ1) T-cells, respectively, both of which are increased in many solid cancers and help maintain a pro-tumoral environment. Read more. . .

Back To Top